- Home
- ANAB vs ADAM Comparison
ANAB vs ADAM Comparison
Compare ANAB & ADAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ADAM
- Stock Information
- Founded
- ANAB 2005
- ADAM 2003
- Country
- ANAB United States
- ADAM United States
- Employees
- ANAB N/A
- ADAM N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ADAM Computer Software: Prepackaged Software
- Sector
- ANAB Health Care
- ADAM Technology
- Exchange
- ANAB Nasdaq
- ADAM Nasdaq
- Market Cap
- ANAB 659.6M
- ADAM 660.2M
- IPO Year
- ANAB 2017
- ADAM N/A
- Fundamental
- Price
- ANAB $31.83
- ADAM $6.90
- Analyst Decision
- ANAB Buy
- ADAM
- Analyst Count
- ANAB 10
- ADAM 0
- Target Price
- ANAB $50.63
- ADAM N/A
- AVG Volume (30 Days)
- ANAB 749.6K
- ADAM 781.3K
- Earning Date
- ANAB 11-04-2025
- ADAM 10-29-2025
- Dividend Yield
- ANAB N/A
- ADAM 11.60%
- EPS Growth
- ANAB N/A
- ADAM N/A
- EPS
- ANAB N/A
- ADAM 0.19
- Revenue
- ANAB $123,164,000.00
- ADAM $205,403,000.00
- Revenue This Year
- ANAB $11.40
- ADAM $14.09
- Revenue Next Year
- ANAB $8.17
- ADAM $27.41
- P/E Ratio
- ANAB N/A
- ADAM $35.91
- Revenue Growth
- ANAB 304.17
- ADAM 23.27
- 52 Week Low
- ANAB $12.21
- ADAM $5.02
- 52 Week High
- ANAB $36.54
- ADAM $7.52
- Technical
- Relative Strength Index (RSI)
- ANAB 71.43
- ADAM N/A
- Support Level
- ANAB $29.49
- ADAM N/A
- Resistance Level
- ANAB $32.24
- ADAM N/A
- Average True Range (ATR)
- ANAB 2.08
- ADAM 0.00
- MACD
- ANAB 0.81
- ADAM 0.00
- Stochastic Oscillator
- ANAB 82.04
- ADAM 0.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ADAM Adamas Trust Inc. Common Stock
Adamas Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Geographically operates in USA states California, New York, Florida, New Jersey, Illinois, maximum from California.